

June 2, 2020



Aptose Biosciences Announces Results of Annual Meeting of Shareholders

SAN DIEGO and TORONTO, June 02, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced the voting results from the Company's annual meeting of shareholders held today, June 2, 2020, in (the "Meeting"). A total of 73.21% of the issued and outstanding common shares of the Company were represented by shareholders present or represented by proxy at the Meeting.

The Company is pleased to announce that all of the nominees listed in the proxy statement dated April 24, 2020 were elected as Directors. The results of the vote are detailed below:

Nominee	Votes For	% Votes For	Votes Withheld	% Votes Withheld
Ms. Carol G. Ashe	31,350,450	99.84	49,262	0.16
Dr. Denis Burger	27,579,743	87.83	3,819,969	12.17
Ms. Caroline M. Loewy	31,350,772	99.84	48,940	0.16
Dr. Erich Platzter	31,357,321	99.86	42,391	0.14
Dr. William G. Rice	31,260,354	99.56	139,358	0.44
Dr. Mark D. Vincent	31,358,492	99.87	41,220	0.13
Mr. Warren Whitehead	31,358,562	99.87	41,150	0.13

Aptose shareholders also voted to re-appoint KPMG LLP as the independent registered public accounting firm of the Company.

Please refer to the Company's management proxy circular available on SEDAR at www.sedar.com or EDGAR <https://www.sec.gov/edgar.shtml> for more details on the matters covered at the Meeting. Final voting results on all matters voted on at the Meeting will also be filed on SEDAR and EDGAR.

About Aptose Biosciences

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: CG-806, an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1 trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies; APTO-253, the only clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk

myelodysplastic syndrome (MDS). For further information, please visit www.aptose.com.

For further information, please contact:

Aptose Biosciences Inc.

Greg Chow
Executive Vice President, CFO
858-926-2730
gchow@aptose.com

LifeSci Advisors, LLC

Dan Ferry, Managing Director
617-535-7746
Daniel@LifeSciAdvisors.com

SMP Communications

Susan Pietropaolo
201-923-2049
susan@smpcommunications.com



Source: Aptose Biosciences, Inc.